Medicare AI Reimbursement: Who Wins the Billion-Dollar Race?

The Centers for Medicare and Medicaid Services (CMS) is redrawing the map for artificial intelligence in healthcare, especially for remote patient monitoring (RPM) and therapeutic monitoring. As the CMS Physician Fee Schedule changes, new reimbursement codes and payment policies are creating a real gap between the financial prospects for specialized AI developers and traditional hardware companies. What follows is a breakdown of these policy shifts to show who’s set to win, who’s likely to lose, and what it all means for healthcare investors, reimbursement strategists, and digital health execs trying to make sense of this market.

The Shifting Sands of Remote Monitoring Reimbursement

The entire re-evaluation of this market comes down to the details of how CMS pays for remote physiological monitoring. For years, most RPM solutions were just bundled services locked into proprietary hardware. That model is now being seriously challenged by sophisticated AI-native software platforms, many of which operate as Software as a Medical Device (SaMD). If you dig into the AMA CPT code utilization data for RPM, you can see how the billing is happening, and it reveals a clear trend: the money is starting to follow the intellectual property in the AI algorithms, not the physical device. This is getting even more pronounced as the industry gets more regulatory clarity from things like the ECRI AI healthcare hazard 2026 outlook and the AMA’s AI healthcare oversight 2026 initiatives. These guidelines are going to directly shape the investment case for any AI solution, putting a premium on those that can prove they’re compliant and clinically effective, which all comes back to having a clear path to getting paid.

Hardware-Dependent Models: Facing Headwinds

Companies that built their businesses around hardware for remote monitoring are starting to feel the pressure. Their models require a ton of capital for manufacturing, shipping, and maintaining physical devices. That hardware is necessary for collecting data, of course, but the value (and the reimbursement) is quickly moving to the software that turns that raw data into something a doctor can actually use. Take iRhythm Technologies. They’ve done a great job building a market with their Zio XT patch for cardiac monitoring, but their model is still heavily dependent on a piece of hardware. They have a powerful competitive advantage in their “data moat”, millions of labeled ECG recordings, but the costs tied to producing and managing a physical product are a constant drag on margins. As CMS keeps tweaking the Physician Fee Schedule, it’s likely the reimbursement for the hardware itself will get squeezed, favoring pure software that can deliver the same (or better) diagnostic results. How the AMA CPT code updates play out will basically determine the long-term profitability for these hardware-inclusive business models.

Pure-Play Software Platforms: The AI-Native Advantage

On the other hand, companies built from the ground up around AI (so-called AI-Native Companies) are in a fantastic position to benefit from these reimbursement changes. These platforms don’t make their own hardware. They use existing or commoditized devices to get the data. Their real product is the sophisticated algorithm that analyzes the data, spots problems, and gives doctors decision support. This SaMD approach is much more scalable, requires less capital, and allows for much faster product updates, especially if they’re using a Predetermined Change Control Plan (PCCP) framework approved by the FDA FDA guidance on AI/ML medical device change control. Biofourmis is a perfect example of this. Their AI platform is all about delivering personalized care through advanced analytics. By focusing on the intelligence they create from the data, Biofourmis aligns perfectly with a reimbursement system that’s starting to pay for better clinical outcomes and efficiency, not for the data-collection device. Their ability to pull in data from different sources to create a full picture makes them very attractive as CMS and other payers move toward value-based care. The low overhead of being a pure software company means higher potential margins, especially as CPT codes are rewritten to reward algorithmic sophistication and clinical proof.

Key Investment Areas Benefiting from Favorable Coding Trends

For healthcare investors and reimbursement strategists, the message is simple: put your money on AI solutions where the value is in the software’s analytical power, not in proprietary hardware.

• SaMD with Strong Clinical Evidence: Prioritize investments in SaMD solutions that have solid clinical validation showing they either improve patient outcomes or lower healthcare costs. Payers are going to demand Real-World Evidence (RWE) to back up these claims and justify reimbursement CMS guidance on real-world evidence for medical devices.
• Scalable AI-Native Architectures: Look for companies with AI-native platforms that can easily plug into existing hospital IT systems and adapt as clinical needs change. This includes platforms built from day one with GMLP (Good Machine Learning Practice) principles, which helps avoid regulatory problems down the road.
• Solutions Addressing High-Cost Chronic Conditions: The biggest reimbursement opportunities will likely be for AI platforms that target expensive chronic diseases. Think cardiovascular disease, diabetes, or chronic kidney disease, where good remote monitoring can prevent hospitalizations and other costly events.
• Clear Regulatory Pathways and CPT Code Alignment: Bet on companies that have already been talking to the FDA and have a 510(k) clearance or De Novo classification. A clear strategy for getting a Category I CPT code, like we’ve seen with some ECG-AI tools, creates a huge reimbursement advantage and reduces risk.
  

  Methodology and Source Note

  This analysis is based on a review of the latest CMS Physician Fee Schedule final rules and proposed changes, as well as public AMA CPT code updates. I’m also drawing conclusions from the financial disclosures and investor calls of companies in this space, including iRhythm Technologies and Biofourmis. The thinking here reflects a financial modeling perspective focused on how these Medicare payment policies will impact different stakeholders.

  Conclusion

  The new Medicare reimbursement for remote monitoring AI isn’t going to benefit everyone equally. It’s creating a clear advantage for AI-native, software-only platforms over the old hardware-based models. Healthcare investors and reimbursement strategists need to look past the marketing and critically assess a company’s core technology, business model, and regulatory homework. The winners will be the ones that can prove their clinical value with a scalable SaMD solution and show a clear, defensible path to CPT code reimbursement. The upcoming ECRI AI healthcare hazard 2026 and AMA AI healthcare oversight 2026 guidelines just reinforce this point, if you don’t have your regulatory and algorithmic house in order, you won’t succeed long-term.